Advertisement

Bupropion Hydrochloride 24 hour ER Tablets

[21 July 2014]

Products Affected - Description

Bupropion hydrochloride 24 hour extended-release tablets, Actavis
150 mg tablets, 30 count (NDC 00591-3331-30)
150 mg tablets, 90 count (NDC 00591-3331-19)
150 mg tablets, 500 count (NDC 00591-3331-05)
300 mg tablets, 30 count (NDC 67767-0142-30)
300 mg tablets, 30 count (NDC 00591-3332-30) - discontinued
 
Bupropion hydrochloride 24 hour extended-release tablets, Global Pharmaceuticals
150 mg tablets, 30 count (NDC 00115-6811-08)
150 mg tablets, 90 count (NDC 00115-6811-10)

Bupropion hydrochloride 24 hour extended-release tablets, Mylan Pharmaceuticals
300 mg tablets, 500 count (NDC 00378-2009-05)

Bupropion hydrochloride 24 hour extended-release tablets, Mylan Institutional
150 mg tablets, unit-dose, 100 count (NDC 51079-0047-20)
300 mg tablets, unit-dose, 30 count (NDC 51079-0109-03)

Bupropion hydrochloride 24 hour extended-release tablets, Par
150 mg tablets, 30 count (NDC 10370-0101-03)
150 mg tablets, 500 count (NDC 10370-0101-50)

Reason for the Shortage

  • Global and Par state the reason for the shortage is increased demand for product.
  • Mylan cannot provide a reason for the shortage.

Available Products

Bupropion hydrochloride 24 hour extended-release tablets, Actavis
300 mg tablets, 90 count (NDC 67767-0142-90)
300 mg tablets, 500 count (NDC 67767-0142-05)
 
Bupropion hydrochloride 24 hour extended-release tablets, Mylan Pharmaceuticals
150 mg tablets, 90 count (NDC 00378-2008-77)

Bupropion hydrochloride 24 hour extended-release tablets, Par
300 mg tablets, 30 count (NDC 10370-0102-03)
300 mg tablets, 500 count (NDC 10370-0102-50)

Wellbutrin XL, Valeant
150 mg tablets, 30 count (NDC 00187-0730-30)
150 mg tablets, 90 count (NDC 00187-0730-90)
300 mg tablets, 30 count (NDC 00187-0731-30)

Forfivo XL, Edgemont
450 mg tablets, 30 count (NDC 49909-0010-30)

Estimated Resupply Dates

  • Actavis has bupropion XL 300 mg tablets in 30 count on back order and the company cannot estimate a release date. All Actavis bupropion XL 150 mg tablets are temporarily unavailable.
  • Global Pharmaceuticals is allocating bupropion XL 150 mg tablets in the 30 count presentation. Bupropion XL 150 mg tablets in the 90 count presentation are on intermittent back order and the company is shipping product as it becomes available.
  • Mylan Pharmaceuticals has bupropion XL 300 mg tablets on back order and the company estimates a release date in early-August 2014.
  • Mylan Institutional has bupropion XL 300 mg unit dose tablets on back order with an estimated release date of early-September 2014. Bupropion XL 150 mg unit dose tablets are on back order and the company cannot estimate a release date.
  • Par has bupropion XL 150 mg tablest on intermittent back order and the company is shipping product as it becomes available.

Updated

July 21, 2014; June 26, 2014; June 12, 2014; May 21, 2014; May 7, 2014, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement